Status:
COMPLETED
Urinary Retention Following taTME VS laTME Total Mesorectal Excision for Rectal Cancer
Lead Sponsor:
Yanhong Deng
Conditions:
Rectal Cancer
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
A comprehensive study with prospectively collected data. These patients were assigned to either the taTME group or the laTME group according to the surgery procedure received
Detailed Description
Transanal total mesorectal excision has emerged as a potential solution to certain limitations associated with laparoscopic total mesorectal excision in rectal cancer patients. Differences in surgical...
Eligibility Criteria
Inclusion
- Age range from 18 to 65 years,
- Diagnosed with rectal cancer at clinical tumor node metastasis stages II or III.
- Palpable tumor determined by digital rectal examination or proctoscopy
- The distal border of the tumor located within 12 cm from the anal verge
Exclusion
- Patients presenting clear indications of pelvic side wall involvement or distant metastasis
- Uncontrolled hypertension or cardiovascular disease
- Patients with synchronous colon cancer
- History of other malignancies within the past 5 years
Key Trial Info
Start Date :
January 30 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 30 2023
Estimated Enrollment :
526 Patients enrolled
Trial Details
Trial ID
NCT06147492
Start Date
January 30 2016
End Date
October 30 2023
Last Update
November 27 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.